Cardiovascular Inflammation Reduction Trial (CIRT)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Sponsor: Brigham and Women's Hospital
A PHASE3 clinical study on Cardiovascular Disease, this trial is completed. The trial is conducted by Brigham and Women's Hospital and has accumulated 13 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — Aug 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .